Insulin resistance in type 1 diabetes: What is 'double diabetes' and what are the risks?

Diabetologia

Volumn 56, Issue 7, 2013, Pages 1462-1470

  Cleland, S J ^a   Fisher, B M ^b   Colhoun, H M ^c   Sattar, N ^d   Petrie, J R ^d  

^a ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular disease; Double diabetes; HDL cholesterol; Hepatic fat; Insulin resistance; Metabolic syndrome; Obesity; Review; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID;

BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DOUBLE DIABETES; ESTIMATED GLUCOSE DISPOSAL RATE; FATTY LIVER; GLYCEMIC CONTROL; HUMAN; HYPOINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE;

EID: 84878887803     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2904-2     Document Type: Review

References (59)

1. Teupe B, Bergis K (1991) Epidemiological evidence for "double diabetes". Lancet 337:361-362
2. Wilkin TJ (2009) The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type 1 as well as type II diabetes. Int J Obes 33:716-726
3. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH (1998) Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 15:418-426
4. Erbey JR, Kuller LH, Becker DJ, Orchard TJ (1998) The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 21:610-614
5. Petrie JR, Pearson ER, Sutherland C (2011) Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. Biochem Pharmacol 81:471-477
6. Williams D, Erbey J, Becker D, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626-632
7. Heptulla RA, Stewart A, Enocksson S et al (2003) In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res 53:830-835
8. Perseghin G, Lattuada G, Danna M et al (2003) Insulin resistance, intramyocellular lipid content and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 285:E1174-E1181
9. Perseghin G, Lattuanda G, De Cobelli F et al (2005) Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia 48:2615-2621
10. Makimattila S, Virkamaki A, Malmstrom R, Urtiainen T, Yki-Jarvinen H (1996) Insulin resistance in type 1 diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab 81:707-712
11. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G (1993) Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883-887
12. Kacerovsky M, Brehm A, Chmelik M et al (2011) Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. J Intern Med 269:189-199
13. Nadeau KJ, Regensteiner JG, Bauer TA et al (2010) Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 95:513-521
14. Maahs DM, Hokanson JE, Wang H et al (2010) Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. Diabetes 59:1771-1779
15. Maahs DM, Nadeau K, Snell-Bergeon JK et al (2011) Association of insulin sensitivity to lipids across the lifespan in people with type 1 diabetes. Diabet Med 28:148-155
16. Schauer IE, Snell-Bergeon JK, Bergman BC et al (2011) Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes 60:306-314
17. Orchard TJ, Olson JC, Erbey JR et al (2003) Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diabetes Care 26:1374-1379
18. Zgibor JC, Ruppert K, Orchard TJ et al (2010) Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diabetes Res Clin Pract 88:314-321
19. Kilpatrick ES, Rigby AS, Atkin SL (2007) Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 30:707-712
20. Chaturvedi N, Sjolie A-K, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284-289
21. Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30:1248-1254
22. Thorn LM, Forsblom C, Waden J, Finnish Diabetic Nephropathy (FinnDiane) Study Group et al (2009) Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32:950-952
23. Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927-1935
24. Nathan DM, Cleary PA, Backlund JY, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653
25. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
26. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD (1998) Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 280:140-146
27. Purnell JQ, Dev RK, Steffes MW et al (2003) Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 52:2623-2629
28. Conway B, Miller RG, Costacou T et al (2009) Adiposity and mortality in type 1 diabetes. Int J Obes 33:796-805
29. Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B, EURODIAB Prospective Complications Group (2006) Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure in type 1 diabetes. Diabet Med 23:557-564
30. Taylor AM, Dunger DB, Grant DB, Preece MA (1988) Somatomedin-C/IGF-1 measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 9:177-181
31. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP (1990) Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 71:1356-1362
32. Norbert S, Konstantinos K, Hans-Ulrich H (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939-960
33. Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749
34. Savage DB, Semple RK (2010) Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 21:329-336
35. Hodson L, Frayn KN (2011) Hepatic fatty acid partitioning. Curr Opin Lipidol 22:216-224
36. Christ ER, Carroll PV, Albany E et al (2001) Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol 55:777-787
37. Vethakkan SR, Walters JM, Gooley JL et al (2012) Normalized NEFA dynamics during an OGTT after islet transplantation. Transplantation 94:e49-e51
38. 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51:1022-1027
39. Yazici D, Ozben B, Yavuz D et al (2011) Epicardial adipose thickness in type 1 diabetic patients. Endocrine 40:250-255
40. Nikkila EA, Hormila P (1978) Serum lipids and lipoproteins in insulin-treated diabetes: demonstration of increased high density lipoprotein concentrations. Diabetes 27:1078-1086
41. Taskinen MR (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41:12-17
42. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O'Connor J, Van Tol A (2002) Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 51:3300-3305
43. Guy J, Ogden L, Wadwa RP et al (2009) Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care 32:416-420
44. Bain SC, Gill GV, Dyer PH et al (2003) Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med 20:808-811
45. Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280-2288
46. Taskinen MR (1987) Lipoprotein lipase in diabetes. Diabetes Metabol Rev 3:551-570
47. James RW, Pometta D (1990) Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 39:1158-1164
48. Caixas A, Perez A, Payes A et al (1998) Effects of short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus. Metabolism 47:371-376
49. Sibley SD, Palmer JP, Hirsch IB, Brunzell J (2003) Visceral obesity, hepatic lipase activity, and dyslipidaemia in type 1 diabetes. J Clin Endocrinol Metab 88:3379-3384
50. Ruotolo G, Parlavecchia M, Taskinen MR et al (1994) Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 17:6-12
51. Petruzzo P, Badet L, Lefrancois N et al (2006) Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med 23:654-659
52. Frystyk J, Ritzel RA, Maubach J et al (2008) Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact of glucose regulatory hormones and the growth hormone/insulin-like growth factor axis. J Clin Endocrinol Metab 93:1758-1766
53. Nevalainen P, Lahtela JT, Mustonen J, Pasternack A (1997) The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant 12:145-150
54. Selam J-L, Kashyap M, Alberti KGMM et al (1989) Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type 1 diabetes mellitus. Metabolism 38:908-912
55. Lahtela JT, Mustonen J, Pasternack A (1995) Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type 1 diabetic patients on continuous ambulatory peritoneal dialysis. Clin Sci 88:427-432
56. Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572-580
57. Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321
58. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR (2010) The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53:809-820
59. REMOVAL: http://clinicaltrials.gov/ct2/show/NCT01483560?term= REMOVAL&rank=1